Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer

被引:129
|
作者
D'Amico, AV
Schultz, D
Loffredo, M
Dugal, R
Hurwitz, M
Kaplan, I
Beard, CJ
Renshaw, AA
Kantoff, PW
机构
[1] Brigham & Womens Hosp, Joint Ctr Radiat Therapy, Boston, MA 02115 USA
[2] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[3] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA
[4] Brigham & Womens Hosp, Beth Israel Deaconess Med Ctr, Dept Radiat Oncol, Boston, MA 02115 USA
[5] Millersville Univ, Dept Math, Millersville, PA 17551 USA
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2000年 / 284卷 / 10期
关键词
D O I
10.1001/jama.284.10.1280
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context Combined treatment using radiation therapy (RT) and androgen suppression therapy (AST) is used to treat men with clinically localized adenocarcinoma of the prostate, but outcome using this combined therapy compared with RT alone is not known. Objective To determine the relative efficacy of RT plus AST vs RT alone among men with clinically localized prostate cancer. Design, Setting, and Patients Retrospective cohort study of 1586 men with prostate cancer who were treated between January 1989 and August 1999 using 3-dimensional conformal RT with (n = 276) or without (n = 1310) 6 months of AST. Main Outcome Measure Relative risk (RR) of prostate-specific antigen (PSA) failure (defined according to the American Society for Therapeutic Radiology and Oncology consensus statement), by treatment and high-, intermediate-, or low-risk group based on serum PSA level, biopsy Gleason score, and 1992 American Joint Commission on Cancer clinical tumor category. Results Estimates of 5-year PSA outcome after RT with or without AST were not statistically different among low-risk patients (P = .09), whereas intermediate- and high risk patients treated with RT plus AST had significantly better outcomes than those treated with RT alone (P < .001 and = .009, respectively). The RR of PSA failure in low-risk patients treated with RT plus AST was 0.5 (95% confidence interval [CI], 0.3-1.1) compared with patients treated with RT alone. The RRs of PSA failure in intermediate-risk and high-risk patients treated with RT plus AST compared with RT alone were 0.2 (95% CI, 0.1-0.3) and 0.4 (95% CI, 0.2-0.8), respectively. Conclusions Our data suggest a significant benefit in 5-year PSA outcomes for men with clinically localized prostate cancer in intermediate- and high-risk groups treated with RT plus AST vs those treated with RT alone. Results from prospective randomized trials currently under way are needed to validate these findings.
引用
收藏
页码:1280 / 1283
页数:4
相关论文
共 50 条
  • [1] Biochemical outcome after radical prostatectomy, external beam radiation therapy or interstitial radiation therapy for clinically localized prostate cancer
    D'Amico, AV
    Whittington, R
    Malkowicz, SB
    Schultz, D
    Blank, K
    Tomaszewski, JE
    Renshaw, AA
    Kaplan, I
    Beard, CJ
    Wein, A
    RENAL, BLADDER, PROSTATE AND TESTICULAR CANCER: AN UPDATE, 2001, : 147 - 157
  • [2] Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer
    D'Amico, AV
    Whittington, R
    Malkowicz, SB
    Schultz, D
    Blank, K
    Broderick, GA
    Tomaszewski, JE
    Renshaw, AA
    Kaplan, I
    Beard, CJ
    Wein, A
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (11): : 969 - 974
  • [3] Biochemical outcome following radical prostatectomy or external beam radiation therapy for clinically localized prostate cancer diagnosed during the PSA era
    D'Amico, AV
    Whittington, R
    Malkowicz, S
    Cote, K
    Loffredo, M
    Schultz, D
    Chen, MH
    Tomaszewski, JE
    Renshaw, AA
    Wein, A
    Richie, JP
    JOURNAL OF UROLOGY, 2002, 167 (04): : 156 - 156
  • [4] The clinical utility of the percent of positive prostate biopsies in predicting biochemical outcome following external-beam radiation therapy for patients with clinically localized prostate cancer
    D'Amico, AV
    Schultz, D
    Silver, B
    Henry, L
    Hurwitz, M
    Kaplan, I
    Beard, CJ
    Renshaw, AA
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2001, 49 (03): : 679 - 684
  • [5] Radiation therapy and androgen suppression as treatment for clinically localized prostate cancer - The new standard?
    DeWeese, TL
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (07): : 864 - 866
  • [6] The impact of supplemental external beam radiation and/or androgen deprivation therapy on biochemical outcome following permanent prostate brachytherapy
    Reed, D
    Merrick, G
    Butler, W
    Wallner, K
    Galbreath, R
    Lief, J
    Allen, Z
    Adamovich, E
    RADIOTHERAPY AND ONCOLOGY, 2004, 71 : S19 - S20
  • [7] Cost effectiveness of androgen suppression plus radiation therapy for clinically localized prostate cancer.
    Wang, SJ
    Herman, TS
    Thomas, CR
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 530S - 530S
  • [8] Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer
    Voog, Justin C.
    Smith, Matthew R.
    Efstathiou, Jason A.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2016, 315 (10): : 1054 - 1055
  • [9] Hemoglobin levels do not predict biochemical outcome for localized prostate cancer treated with neoadjuvant androgen-suppression therapy and external-beam radiotherapy
    Pai, Howard Huaihan
    Ludgate, Charles
    Pickles, Tom
    Paltiel, Chuck
    Agranovich, Alex
    Berthelet, Eric
    Duncan, Graeme
    Kim-Sing, Charmaine
    Kwan, Winkle
    Lim, Jan
    Liu, Mitchell
    Tyldesley, Scott
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 65 (04): : 990 - 998
  • [10] Outcome for surgically staged localized prostate cancer treated with external beam radiation therapy
    Lawrence, G
    JOURNAL OF UROLOGY, 1998, 159 (03): : 996 - 996